Home
Clinical Resources Search
PQI: Duvelisib (Copiktra®) for Chronic Lymphocytic Leukemia

Duvelisib (Copiktra®) for Chronic Lymphocytic Leukemia

Download PQI pdf

Last Updated: November 14, 2023

By: Linda Frisk, PharmD

About this PQI

The purpose of this PQI is to provide background on PI3K inhibition and review clinical considerations for duvelisib therapy in order to optimize outcomes for cancer patients as well as identifying the patients with malignant lymphoma who may be candidates for duvelisib.

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care.

Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Frequently Searched

Supported by

Duvelisib (Copiktra®) for Chronic Lymphocytic Leukemia

About this PQI

How to Use a Positive Quality Intervention (PQI)

Find Similar Resources

PQI: Administration of Subcutaneous Isatuximab-irfc (SARCLISA ESCENA) via the CirCLIQ On-Body Delivery System

PQI: Teclistamab-cqyv (Tecvayli) in Combination with Daratumumab and Hyaluronidase-fihj (Darzalex Faspro) for Relapsed Multiple Myeloma

PQI: Tafasitamab-cxix (Monjuvi) for Relapsed/Refractory Follicular Lymphoma

PQI: Encorafenib (Braftovi) + Cetuximab (Erbitux) + FOLFIRI for BRAF V600E-Positive Metastatic Colorectal Cancer

PQI in Action: Inavolisib (Itovebi) Patient Management

PQI in Action: Revumenib (Revuforj) for the Management of Acute Leukemia

PQI in Action: Capivasertib (Truqap) Patient Management

PQI in Action: Sutimlimab-jome (Enjaymo) for the Management of Hemolysis in Cold Agglutinin Disease (CAD)

S11 E8: The Future of Oncology

S11 E7: Your Health Story in One Place

S11 E6: Finding the Heart of Oncology

S11 E5: Keep Marching On: Changing the Story of Pancreatic Cancer

Toolkit: Simplify CLL Tracking in Oncology Practices

Toolkit: Optimize CLL Care in Epic

Treatment Support Kit: Elranatamab

Treatment Support Kit: Bispecific (T-Cell Engager)

Treatment Support Kit: Zanidatamab-hrii

Treatment Support Kit: Avutometinib and Defactinib

Video: Akynzeo® (Ready-to-Use Vial): A Step-by-Step Video Guide

Video: Ibrutinib-Related Cardiac Toxicities: Management & Dose Modifications

Video: Neratinib for Extended Adjuvent Treatment of Adult Patients with Early-Stage HER2-Positive Breast Cancer (MIP)

Video: BRUKINSA® (Zanubrutinib) for Treatment of Relapsed or Refractory Marginal Zone Lymphoma

Acalabrutinib

Tafasitamab, Rituximab, and Lenalidomide

PQI: Tafasitamab-cxix (Monjuvi) for Relapsed/Refractory Follicular Lymphoma

Obinutuzumab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

Obinutuzumab and Cyclophosphamide, Vincristine, and Prednisone

S7 Ep 8: Sickle Cell Disease Insights

S11 E3: Beyond Borders: Bringing Cancer Treatment Within Reach

High-Dose Cytarabine

High-Dose Methotrexate

Revumenib

Duvelisib

Duvelisib

S11 E8: The Future of Oncology

PQI: Administration of Subcutaneous Isatuximab-irfc (SARCLISA ESCENA) via the CirCLIQ On-Body Delivery System

Trastuzumab, Carboplatin, and Paclitaxel

Pembrolizumab, Bevacizumab, Cisplatin, and Paclitaxel